Company profile
Lexicon Pharmaceuticals, Inc.
NASDAQ: LXRX · Healthcare · Biotechnology
#439 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
59CFH 57DQ 61GM 55SS 75
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), listing tenure · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$69.6M
Rev growth YoY (TTM)
+123.1%
Net income (FY)
-$50.3M
Employees
81
as of 2026-08-10
Market cap
$1.1B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$49.8M$49.8M2025
Net income-$50.3M-$50.3M2025
Operating income-$48.9M-$48.9M2025
Total assets$185.0M$185.0M2025
Liabilities$77.4M$77.4M2025
Equity$107.5M$107.5M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY19
FY19
FY19
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License91%
Product9%
By geography
Not disclosed.
The read
What is Lexicon Pharmaceuticals, Inc.’s revenue?
Lexicon Pharmaceuticals, Inc. booked $49.8M in FY2025 revenue, growing 730% year over year — faster than 95% of Healthcare companies we track, at a -101.1% net margin.
Peers · Healthcare
Carlsmed, Inc.54DMinerva Surgical, Inc.——Charlotte's Web Holdings, Inc.44DBioqual, Inc.65BGossamer Bio, Inc.24DShoulder Innovations, Inc.42DNeighbors
Montgomery →Key facts
CEOMichael S. Exton
SectorHealthcare
IndustryBiotechnology
HeadquartersThe Woodlands, TX
ExchangeNASDAQ: LXRX
Employees81
IPO date2000-04-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.